KoBioLabs고바이오랩
348150 · KOSDAQ · ₩348150 · 고바이오랩
- Market cap
- ₩53B
- Enterprise value
- ₩23B
- P/E
- —
- P/B
- 1.9×
- Dividend yield
- 0.0%
- ROE
- −16.7%
- Net margin
- −6.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−68.5% from the high
₩2,310Today: ₩2,600 – ₩2,750₩8,730
Returns
- 1W−3.3%
- 1M+3.2%
- 3M−11.1%
- 6M−48.7%
- YTD−52.0%
- 1Y−47.7%
- Volume today
- 18,068
- 0.9× the 20-day average
- Traded today
- ₩48M
- Listed shares
- 19,418,889
- EPS (12 months)
- −₩247
- Earnings yield −9.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+5.2% on Oct 27, 2026.
- • Foreign investors bought a net ₩6M that day
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumFlat5.4% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
KoBioLabs stock overview
KoBioLabs (고바이오랩, KRX: 348150) is listed on KOSDAQ, in the Biotech & Pharma sector. Go Bio Lab is a Korean microbiome-based biotech company developing microbiome drug candidates across immunology, allergy, metabolic, inflammatory bowel, autism spectrum disorder, and oncology areas, using its Smartiome platform for candidate discovery through clinical development. Its shares closed at ₩2,750 on Oct 27, 2026, up 5.16% on the day, giving it a market value of ₩53B.
Key facts
- Market cap
- ₩53B
- Sector
- Biotech & Pharma
- Latest price change
- +5.16%
- As of
- Oct 27, 2026
- Main business
- Go Bio Lab is a Korean microbiome-based biotech company developing microbiome drug candidates across immunology, allergy, metabolic, inflammatory bowel, autism spectrum disorder, and oncology areas, using its Smartiome platform for candidate discovery through clinical development.
Quick answers about KoBioLabs
- What does KoBioLabs do?
- Go Bio Lab is a Korean microbiome-based biotech company developing microbiome drug candidates across immunology, allergy, metabolic, inflammatory bowel, autism spectrum disorder, and oncology areas, using its Smartiome platform for candidate discovery through clinical development. Its business model centers on licensing out first-in-class or best-in-class drug candidates. Through its subsidiary WeBiome, which was established with E-Mart in 2022, it develops and sells health functional food and probiotic products through home shopping and online channels, and its drug candidates have been licensed to SPH Sine Pharmaceutical in Greater China.
- What is the market cap of KoBioLabs?
- The market capitalisation of KoBioLabs was ₩53B at the close on Oct 27, 2026.
- Who are the largest shareholders of KoBioLabs?
- According to the latest official filings, the largest reported holders are EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.04%, as of Jul 31, 2026); Dimensional World ex. U.S. Core Equity 2 ETF (0.02%, as of Jul 31, 2026).
- When is the next earnings report from KoBioLabs?
- Korean companies rarely announce results dates in advance. Based on when KoBioLabs filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
Go Bio Lab is a Korean microbiome-based biotech company developing microbiome drug candidates across immunology, allergy, metabolic, inflammatory bowel, autism spectrum disorder, and oncology areas, using its Smartiome platform for candidate discovery through clinical development. Its business model centers on licensing out first-in-class or best-in-class drug candidates. Through its subsidiary WeBiome, which was established with E-Mart in 2022, it develops and sells health functional food and probiotic products through home shopping and online channels, and its drug candidates have been licensed to SPH Sine Pharmaceutical in Greater China.
Written by AI from the company's latest annual report.
- Korean name
- 고바이오랩
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이한승
- Founded
- Aug 2014
- Listed
- Nov 2020
- Listed shares
- 19,418,889
- Fiscal year ends
- Month 12
- Website
- kobiolabs.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Half-year report (Jun 2026)Aug 13, 2026
- Quarterly report (Mar 2026)May 14, 2026
- Amended: Annual general meeting resultsMar 27, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsMar 27, 2026
- Change of CEOMar 26, 2026
Titles in Korean until English translations are added.
Also known as: KoBioLabs / 고바이오랩 / 348150 / KRX:348150
Source: KRX statistical information